Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-UP vs step-down strategies in childhood arthritis
2023-505051-43-00Phase 3Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of etanercept and methotrexate in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoint: Clinical remission at 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
etanerceptmethotrexate
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2023-505051-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505051-43-00.